CNS publicizes $20.13 million public sale of stock with 15% greenshoe

Drug developer sells shares to finance its general corporate purposes

By Devika Patel

Knoxville, Tenn., May 5 - CNS Response, Inc. will conduct a public sale of stock for up to $20,125,000 with a 15% greenshoe, according to an S-1 filed Thursday with the Securities and Exchange Commission.

The Aliso Viejo, Calif.-based company will sell common shares to fund marketing, program implementation, research and development projects and capital expenditures as well as debt repayment and general corporate purposes.

Paradigm Capital U.S. Inc. and Mackie Research USA Inc. are the agents.

CNS Response develops and commercializes new indications of approved drugs and drug candidates

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.